Form 4: Quince Therapeutics Director Acquires Stock Options in Lieu of Cash Retainer
SEC Form 4 Filing
Director June Bray acquired 30,282 stock options in Quince Therapeutics in lieu of a cash retainer.
Summary
- June Bray, a director at Quince Therapeutics, acquired 30,282 stock options on January 2, 2025.
- These options were granted in lieu of the annual director cash retainer for 2025.
- The options have an exercise price of $1.88 and will vest in equal quarterly installments over one year.
- The options expire on January 2, 2035.
Sentiment
Score: 7
Explanation: The document reflects a standard compensation practice, which is generally positive as it aligns director interests with shareholders. There are no negative implications.
Positives
- The director's decision to take stock options instead of cash may indicate confidence in the company's future performance.
- The vesting schedule aligns the director's interests with the company's long-term success.
Management Comments
- The Reporting Person elected to receive the stock options in lieu of the annual director cash retainer for 2025 provided for under the Issuer's Outside Director Compensation Policy.
Industry Context
It is common practice for companies to offer stock options to directors as part of their compensation packages, aligning their interests with those of shareholders.
Comparison to Industry Standards
- Granting stock options to directors is a standard practice across the industry, often used to incentivize performance and align interests with shareholders.
- The vesting schedule of one year is also a common practice, ensuring that directors have a long-term stake in the company's success.
- The specific number of options and exercise price would be specific to the company and the director's role.
Stakeholder Impact
- Shareholders may view the stock option grant positively as it aligns the director's interests with the company's performance.
- The director is incentivized to contribute to the company's success to increase the value of their options.
Key Dates
| Date | Description |
|---|---|
| 01/02/2025 | Date of the stock option grant and the start of the vesting period. |
| 01/08/2025 | Date the form was signed by the Attorney-in-Fact. |
| 01/02/2035 | Expiration date of the stock options. |
Keywords
stock options, director compensation, insider trading, Quince Therapeutics, QNCX, equity, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.